Tobias Wengenmayer

Prof. Dr. Tobias Wengenmayer


Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 June 2017 in Critical Care
Verified
Journal Article
Open access
PDF file
TWTobias Wengenmayer
Tobias Wengenmayer
SRStephan Rombach
Stephan Rombach
FRFlorian Ramshorn
Florian Ramshorn
PBPaul Marc Biever
Paul Marc Biever
CBChristoph Bode
Christoph Bode
DSDawid L. Staudacher
Dawid L. Staudacher
Venoarterial extracorporeal membrane oxygenation (VA-ECMO) support under extracorporeal cardiopulmonary resuscitation (eCPR) is the last option and may be offered to selected patients. Several factors predict outcome in these patients, including initial heart rhythm, comorbidities, and bystander cardiopulmonary resuscitation (CPR). We evaluated outcomes of all VA-ECMO patients treated within the last 5 years at our center in respect to low-flow duration during CPR. We report retrospective registry data on all patients with eCPR treated at a university hospital between October 2010 and May 2016. A total of 133 patients (mean age 58.7 ± 2.6 years, Simplified Acute Physiology Score II score at admission 48.1 ± 3.4) were included in the analysis. The indication for eCPR was either in-hospital or out-of-hospital cardiac arrest without return of spontaneous circulation (n = 74 and 59, respectively). There was a significant difference in survival rates between groups (eCPR in-hospital cardiac arrest [IHCA] 18.9%, eCPR out-of-hospital cardiac arrest [OHCA] 8.5%; p < 0.042). Mean low-flow duration (i.e., duration of mechanical CPR until VA-ECMO support) was 59.6 ± 5.0 minutes in all patients and significantly shorter in IHCA patients than in OHCA patients (49.6 ± 5.9 vs. 72.2 ± 7.4 minutes, p = 0.001). Low-flow time strongly correlated with survival (p < 0.001) and was an independent predictor of mortality. Time to full support is an important and alterable predictor of patient survival in eCPR, suggesting that VA-ECMO therapy should be established as fast as possible in the selected patients destined for eCPR.

1 April 2005 in Placenta
Verified
Journal Article
Closed access
TPT.G. Poehlmann
T.G. Poehlmann
JFJ.S. Fitzgerald
J.S. Fitzgerald
AMAnja Meissner
Anja Meissner
TWTobias Wengenmayer
Tobias Wengenmayer
ESE. Schleussner
E. Schleussner
UMU.R. Markert
U.R. Markert

1 February 2017 in Journal of Critical Care
Verified
Journal Article
Closed access
DSDawid L. Staudacher
Dawid L. Staudacher
WGWolfgang Gold
Wolfgang Gold
PBPaul M. Biever
Paul M. Biever
CBChristoph Bode
Christoph Bode
TWTobias Wengenmayer
Tobias Wengenmayer

6 January 2022 in Critical Care
Verified
Journal Article
Open access
PDF file
MGMarco Giani
Marco Giani
Emanuele RezoagliEmanuele Rezoagli
Emanuele Rezoagli
Christophe GuervillyChristophe Guervilly
Christophe Guervilly
JRJonathan Rilinger
Jonathan Rilinger
TDThibault Duburcq
Thibault Duburcq
AVAndré Vincentelli
André Vincentelli
Background: Prone positioning (PP) reduces mortality of patients with acute respiratory distress syndrome (ARDS). The potential benefit of prone positioning maneuvers during venovenous extracorporeal membrane oxygenation (ECMO) is unknown. The aim of this study was to evaluate the association between the use of prone positioning during extracorporeal support and ICU mortality in a pooled population of patients from previous European cohort studies. Methods: We performed a pooled individual patient data analysis of European cohort studies which compared patients treated with prone positioning during ECMO (Prone group) to “conventional” ECMO management (Supine group) in patients with severe ARDS. Results: 889 patients from five studies were included. Unadjusted ICU mortality was 52.8% in the Supine Group and 40.8% in the Prone group. At a Cox multiple regression analysis PP during ECMO was not significantly associated with a reduction of ICU mortality (HR 0.67 95% CI: 0.42–1.06). Propensity score matching identified 227 patients in each group. ICU mortality of the matched samples was 48.0% and 39.6% for patients in the Supine and Prone group, respectively (p = 0.072). Conclusions: In a large population of ARDS patients receiving venovenous extracorporeal support, the use of prone positioning during ECMO was not significantly associated with reduced ICU mortality. The impact of this procedure will have to be definitively assessed by prospective randomized controlled trials.

1 January 2005
Verified
Book Chapter
Closed access
JFJustine S. Fitzgerald
Justine S. Fitzgerald
SBSusann Busch
Susann Busch
TWTobias Wengenmayer
Tobias Wengenmayer
KFKatharina Foerster
Katharina Foerster
TMTorben de la Motte
Torben de la Motte
UMUdo R. Markert
Udo R. Markert
During the first trimester of pregnancy, well-differentiated primary cells of the placenta known as trophoblast cells grow in an invasive and destructive fashion similar to malignancies, but limited in space and time. The comparison of trophoblast cells with their malignant counterpart, human choriocarcinoma cells, offers an attractive model to understand the origin or development of malignant growth. Several cytokines and growth factors are known to influence trophoblast migration (e.g. EGF, IGF-2, HGF), proliferation (e.g. leptin, HGF, GM-CSF) and/or invasion (e.g. leukemia inhibitory factor, LIF), each factor utilizing at least one pathway for intracellular signaling in the trophoblast. Two pathways that are crossed especially often mediate the signals of these factors and are simultaneously well established in terms of tumor invasion: the Janus kinase-signal transducers and activators of transcription (Jak-Stat) and receptor-associated tyrosine kinase-mitogen-activated protein kinase (RTK-MAPK) pathways. These two pathways are detrimental for reproduction in general, and in part for placenta development, as a series of knockout experiments demonstrate. Aspects of each pathway are also implicated to be involved in trophoblast invasion, e.g. STAT3 is constitutively activated in invasive first trimester trophoblast cells, and activated ERK is detectable in intermediate trophoblast cells, an invasive phenotype. Interaction at several intersection points between the pathways has been described in several cell systems so that the same would seem to be possible in trophoblast cells. In this review, some of the possible areas of interaction are alluded to.

28 July 2016 in PLOS ONE
Verified
Journal Article
Open access
PDF file
DSDawid L. Staudacher
Dawid L. Staudacher
PBPaul M. Biever
Paul M. Biever
CBChristoph Benk
Christoph Benk
IAIngo Ahrens
Ingo Ahrens
CBChristoph Bode
Christoph Bode
TWTobias Wengenmayer
Tobias Wengenmayer
Bleeding is a frequent complication in patients on venoarterial extracorporeal membrane oxygenation (VA-ECMO). An indication for dual antiplatelet therapy due to coronary stent implantation is present in a considerable number of these patients. The objective of this retrospective study was to evaluate if dual antiplatelet therapy (DAPT) significantly increases the high intrinsic bleeding risk in patients on VA-ECMO. A total of 93 patients were treated with VA-ECMO between October 2010 and October 2013. Average time on VA-ECMO was 58.9 ± 1.7 hours. Dual antiplatelet therapy was given to 51.6% of all patients. Any bleeding was recorded in 60.2% of all patients. There was no difference in bleeding incidence in patients on DAPT when compared to those without any antiplatelet therapy including any bleeding (66.7% vs. 57.1%, p = 0.35), BARC3 bleeding (43.8% vs. 33.3%, p = 0.31) or pulmonary bleeding (16.7% vs. 19.0%, p = 0.77). This holds true after adjustment for confounders. Rate of transfusion of red blood cells were similar in patients with or without DAPT (35.4% vs. 28.6%, p = 0.488). Bleeding on VA-ECMO is frequent. This registry recorded no statistical difference in bleeding in patients on dual antiplatelet therapy when compared to no antiplatelet therapy. When indicated, DAPT should not be withheld from VA ECMO patients.